Revista Colombiana de Reumatologia最新文献

{"title":"Efecto de la terapia de inducción con micofenolato o ciclofosfamida sobre los niveles séricos del factor activador de células B (BAFF) en pacientes con lupus eritematoso sistémico","authors":"Alejandra Betancur Herrera ,&nbsp;Juan José Mariño Restrepo ,&nbsp;Tulio Lopera Restrepo ,&nbsp;Laura Robledo Montoya ,&nbsp;Juan Felipe Soto Restrepo ,&nbsp;Adriana Lucía Vanegas García ,&nbsp;Carlos Horacio Muñoz Vahos ,&nbsp;Juan Camilo Díaz Coronado ,&nbsp;Ricardo Antonio Pineda Tamayo ,&nbsp;Gloria Vásquez","doi":"10.1016/j.rcreu.2024.01.001","DOIUrl":"10.1016/j.rcreu.2024.01.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which B cell hyperactivity plays a key role in its pathophysiology. In this disease, the B cell activating factor (BAFF) is implicated in the loss of immunological tolerance, and high concentrations of this factor have been linked to disease progression. It is unknown how induction therapies with cyclophosphamide (CFM) or mycophenolate (MMF) modulate BAFF levels.</div></div><div><h3>Objective</h3><div>To determine how induction therapies modulate BAFF concentrations.</div></div><div><h3>Materials and methods</h3><div>An analytical observational study was performed with 20 patients with SLE from two institutions between 2020-2022, clinical and laboratory information was obtained from medical records. Measurement of serum BAFF levels was performed using an ELISA kit and statistical analyses with GraphPad Prism version 9.</div></div><div><h3>Results</h3><div>20 patients with a diagnosis of SLE, 18 with CFM and 2 with MMF, were included, nine patients at baseline and eleven at 3-6 months. The median BAFF in SLE patients was 902.2 pg/mL and 379.7 pg/mL in healthy controls, statistically significant differences (p<!--> <!-->=<!--> <!-->.0003). BAFF levels were also found to be different among patients treated with antimalarials (p<!--> <!-->=<!--> <!-->.0465) and an inverse correlation with creatinine values and prednisolone doses was also observed.</div></div><div><h3>Conclusions</h3><div>BAFF levels are affected during induction therapy, observing an initial reduction and subsequent recovery at 3-6 months, our results suggest that chloroquine and high doses of prednisolone maintain lower serum BAFF levels.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 118-129"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140282998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potenciales biomarcadores presentes en orina de pacientes con lupus eritematoso sistémico: estudio exploratorio en pacientes colombianos","authors":"Yeimy Paola Trujillo ,&nbsp;Alfonso Kerguelen ,&nbsp;Sandra Amado ,&nbsp;Santiago Bernal-Macías ,&nbsp;Daniel Gerardo Fernández-Ávila ,&nbsp;Alfonso Barreto-Prieto ,&nbsp;Luz-Stella Rodríguez","doi":"10.1016/j.rcreu.2024.02.006","DOIUrl":"10.1016/j.rcreu.2024.02.006","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the urinary levels of molecules related to removing apoptotic cells and triggering inflammation, as well as cytokines involved in Colombian patients with systemic lupus erythematosus without and with lupus nephritis compared to healthy controls.</div></div><div><h3>Materials and methods</h3><div>Urine samples were taken from three groups of patients: healthy controls (n<!--> <!-->=<!--> <!-->7), patients with systemic lupus erythematosus without lupus nephritis (n<!--> <!-->=<!--> <!-->7), and patients with lupus and lupus nephritis (n<!--> <!-->=<!--> <!-->4). The urine sample was collected and concentrated by ultrafiltration. A western blot evaluated HMGB1, Histone H3, Calreticulin (CRT), Annexin A1 and CD46, CX3CL1 by ELISA and cytokines such as IL-8, IL-6, IL-12p70, TNF-α, and IL-1β by flow cytometry.</div></div><div><h3>Results</h3><div>Histone H3 was detected in two patients, one with systemic lupus erythematosus without lupus nephritis and one with systemic lupus erythematosus and lupus nephritis. The detected band suggests a post-translational modification. There were no differences between the levels of HMGB1 and CX3CL1 in the study groups. CD46, Annexin A1, and CRT were not detected in our samples. When evaluating cytokines in urine, an increase in IL-8 was observed in the group of patients with systemic lupus erythematosus without nephritis compared to controls. For IL-6, an increase was found among patients without lupus nephritis when compared with patients with lupus nephritis. No differences were found between the urinary levels of the other cytokines evaluated (IL-12p70, TNF-α, IL-1β, and IL-10).</div></div><div><h3>Conclusion</h3><div>Urinary histone H3 and IL-8 levels may be interesting molecules to be evaluated in more patients with systemic lupus erythematosus, while HMGB1 and CX3CL1 are not useful. Further evaluation of patients is required to confirm these findings.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 159-167"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Características sociodemográficas, clínicas y bioquímicas de pacientes que debutaron con y sin nefritis lúpica en una cohorte de pacientes mexicanos con lupus eritematoso sistémico en un centro de referencia","authors":"Fabiola Pazos-Pérez ,&nbsp;Aida Martínez-Badajoz ,&nbsp;Francisco M. Bravo-Rojas ,&nbsp;Estafanía Garduño-Hernández ,&nbsp;María I. Gil-Arredondo ,&nbsp;Rocío Catana-Hernández ,&nbsp;Mario C. Ocampo-Torres ,&nbsp;Juan C. Hernández-Rivera","doi":"10.1016/j.rcreu.2023.12.008","DOIUrl":"10.1016/j.rcreu.2023.12.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that presents great clinical heterogeneity, so that up to 60% of patients may develop lupus nephropathy (LN).</div></div><div><h3>Objective</h3><div>To identify demographic, clinical, and biochemical characteristics of patients presenting with and without lupus nephritis at the time of SLE diagnosis in a cohort of Mexican patients.</div></div><div><h3>Materials and methods</h3><div>This is a cross-sectional, analytical, and single-centre study. Frequencies and percentages were used for categorical variables and the comparison was made with Pearson's Chi2 statistical test or Fisher's exact test. For the quantitative variables, their distribution was calculated and according to this, Student's t was used in case of normal distribution and Mann-Whitney U for those with free distribution.</div></div><div><h3>Results</h3><div>Of 160 patients, 79 (49.37%) had LN. These individuals had a higher prevalence of serositis (14.3 vs 8.1%, p<!--> <!-->=<!--> <!-->.048) and arterial hypertension (40.50% vs 24.6%, p<!--> <!-->=<!--> <!-->.033), while those without LN had a higher prevalence of rheumatoid arthritis and joint disease (6 vs 1%, p<!--> <!-->=<!--> <!-->.052), allergies (43.2 vs 20.25%, p<!--> <!-->=<!--> <!-->.002), infections (23.45 vs 10%, p<!--> <!-->=<!--> <!-->.020), and lower levels of C3 (52.25<!--> <!-->±<!--> <!-->28.7 vs 74.6<!--> <!-->±<!--> <!-->32.2<!--> <!-->mg/dl, p &lt;<!--> <!-->.001).</div></div><div><h3>Conclusions</h3><div>The characteristics described in our cohort are like those presented in other Latino and Asian series. However, the presence of concomitant infections at the time of SLE diagnosis has not been described and should be considered for future research.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 110-117"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140274096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factores asociados con el diagnóstico de síndrome antifosfolípido: ¿cuándo debemos solicitar los estudios?","authors":"Jaime Andrés Escobar Sáenz ,&nbsp;Oscar Muñoz Velandia ,&nbsp;Paula Ruiz Talero ,&nbsp;Daniel Fernández Ávila","doi":"10.1016/j.rcreu.2024.01.005","DOIUrl":"10.1016/j.rcreu.2024.01.005","url":null,"abstract":"<div><h3>Introduction</h3><div>In clinical practice, there is no established guidance on the timing of sample collection when suspicion of antiphospholipid syndrome (APS) arises. Instead, only a list of risk factors for APS exists, without adequate quantification of the significance of each factor.</div></div><div><h3>Materials and methods</h3><div>Analytical observational case-control study, nested in a retrospective cohort of patients with venous or arterial thrombosis in whom APS was suspected. Patients with a confirmed diagnosis of APS according to the Sapporo criteria or triple positive initial result (cases) were compared with patients negative for APS (controls). The aim was to assess the association between the diagnosis of APS and various clinical and paraclinical factors.</div></div><div><h3>Results</h3><div>68 patients were included (72% women, 41.2% with deep venous thromboembolism and 29.4% with pulmonary embolism). In 18 patients APS was confirmed. There were no significant differences in age in patients with and without confirmation of the diagnosis (44.0<!--> <!-->±<!--> <!-->17.9 vs. 51.2<!--> <!-->±<!--> <!-->14.9, <em>P</em> <!-->=<!--> <!-->.069). In the multivariate analysis, a significant and independent association was found between having APS and rheumatic disease (OR: 12.1, <em>P</em> <!-->=<!--> <!-->.02), PTT prolongation (OR: 17.6, <em>P</em> <!-->=<!--> <!-->.014), platelet count &lt;<!--> <!-->150,000 (OR: 18.6, <em>P</em> <!-->=<!--> <!-->.008), and a history of previous thrombosis events (OR: 6.1 for each event, <em>P</em> <!-->=<!--> <!-->.027).</div></div><div><h3>Conclusions</h3><div>In patients with arterial or venous thrombosis, there is a greater possibility of confirming APS if there is a history of rheumatic disease, prolongation of PTT to more than 5<!--> <!-->seconds, thrombocytopenia, and previous events of thrombotic disease. In these patients, it is advisable to screen for APS, to prevent the further occurrence of thrombotic events.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 137-144"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico","authors":"Santiago Guzmán-García ,&nbsp;Goethe Sacoto-Flores ,&nbsp;Johanna Román-Bermeo ,&nbsp;Fabiana Samaniego-Burneo ,&nbsp;María Ochoa ,&nbsp;Franklin Uguña-Sari ,&nbsp;Gladis Molina-Alvarado ,&nbsp;Luis M. Amezcua-Guerra","doi":"10.1016/j.rcreu.2024.02.004","DOIUrl":"10.1016/j.rcreu.2024.02.004","url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.</div></div><div><h3>Materials and methods</h3><div>An observational multicentre study including patients with SARDs from Ecuador and Mexico.</div></div><div><h3>Results</h3><div>A total of 103 patients (78% women), aged 52.5<!--> <!-->±<!--> <!-->17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR]<!--> <!-->=<!--> <!-->17.07), severe COVID-19 at admission (OR<!--> <!-->=<!--> <!-->11.45), and presence of SLE (OR<!--> <!-->=<!--> <!-->4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR<!--> <!-->=<!--> <!-->15.61).</div></div><div><h3>Conclusions</h3><div>Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 152-158"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efectividad del uso del parche de trinitrato de glicerilo en el fenómeno de Raynaud secundario","authors":"Silvia Méndez-Flores ,&nbsp;Dulce María Carrillo-Córdova ,&nbsp;Rafael López-Loya ,&nbsp;Bruno Estañol-Vidal","doi":"10.1016/j.rcreu.2024.01.002","DOIUrl":"10.1016/j.rcreu.2024.01.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Secondary Raynaud's phenomenon is one of the primary cutaneous manifestations of various rheumatological diseases, which can significantly impact quality of life and whose systemic treatment can lead to several adverse effects. Therefore, this study was conducted to assess the effectiveness of glyceryl trinitrate (in transdermal patch form) in patients with secondary Raynaud's phenomenon (SRP), evaluated through vascular flow photoplethysmography.</div></div><div><h3>Materials and methods</h3><div>A comparative, analytical, open-label, non-randomized study was conducted to evaluate the efficacy of 4.5<!--> <!-->mg of glyceryl trinitrate in a transdermal patch placed on the proximal region of one hand in patients diagnosed with SRP compared to the untreated contralateral hand. To determine the primary outcome, vascular flow photoplethysmography assessment was performed 30 days after daily patch use. Secondary results were obtained using an infrared thermometer to measure local temperature in both hands before patch application, 30<!--> <!-->minutes after patch use, and at the end of the follow-up period. Additionally, various questionnaires, including the Visual Analogue Scale for pain, Raynaud's Condition Score (RCS), and Dermatology Quality of Life Index (DLQI), were administered on the first and last days of the study.</div></div><div><h3>Results</h3><div>Sixteen patients, all female, with a median age of 54 years, were included. Regarding the rheumatological diseases associated with secondary Raynaud's phenomenon, twelve patients (75% of the sample) were associated with systemic sclerosis, three patients (19%) with lupus erythematosus, and one (6%) with mixed connective tissue disease (MCTD). There was a significant increase in peripheral blood flow after 30 days of treatment with 4.5<!--> <!-->mg of glyceryl trinitrate every 24<!--> <!-->hours, along with improvement in clinical symptom and quality of life questionnaires.</div></div><div><h3>Conclusions</h3><div>This study supports the use of low-dose glyceryl trinitrate via transdermal patches to improve vascular flows, translating into short-term clinical symptom improvement associated with SRP.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 130-136"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140274548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"El ABC de la nefritis lúpica","authors":"José A. Gómez-Puerta","doi":"10.1016/j.rcreu.2025.02.001","DOIUrl":"10.1016/j.rcreu.2025.02.001","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 103-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comite Editorial online","authors":"","doi":"10.1016/S0121-8123(24)00107-5","DOIUrl":"10.1016/S0121-8123(24)00107-5","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages E1-E3"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis","authors":"Carlos Andrés Díaz-Garza ,&nbsp;Alejandro Garza-Alpirez ,&nbsp;David Vega-Morales ,&nbsp;Deshiré Alpizar-Rodríguez ,&nbsp;Berenice Carrillo-Haro","doi":"10.1016/j.rcreu.2023.12.007","DOIUrl":"10.1016/j.rcreu.2023.12.007","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Our aim was to know patient's understanding and concerns about biosimilars, switching, and non-medical switch in Mexican population.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional social media survey via the Mexican Foundation for Rheumatic Patients (FUMERAC) was conducted from November 2020 to January 2021. Patients were eligible if they were &gt;18 years of age with any inflammatory rheumatic condition.</div></div><div><h3>Results</h3><div>A total of 165 participants completed the survey. The most frequent diagnoses were Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. Disease-modifying antirheumatic drugs as monotherapy was the most common treatment. Prior or current users of biologics were reported. Most participants had never heard the term biosimilar<span>. Some would accept the change from an originator to its biosimilar and few would take legal measure or file a complaint if a non-medical switch were to happen. Patients had concerns on treatment effectiveness, adverse effects, reason for change, treatment duration, and other patient's experience.</span></div></div><div><h3>Conclusion</h3><div>In Mexico, the concept of biosimilars is barely known. Most patients would not take any measure if they were changed from an originator to its biosimilar.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 105-109"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140091455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common variable immune deficiency complicating proliferative lupus nephropathy: A diagnostic and therapeutic challenge","authors":"Lamia Bengherbia,&nbsp;Said Taharboucht,&nbsp;Oussama Souas,&nbsp;Hassina Chicha,&nbsp;Ahcene Chibane","doi":"10.1016/j.rcreu.2024.02.002","DOIUrl":"10.1016/j.rcreu.2024.02.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Common variable immunodeficiency (CVID) is a rare condition characterized by a constitutional humoral immune deficiency. Its association with systemic lupus is extremely rare.</div></div><div><h3>Case presentation</h3><div>In this case report, we present a 21-year-old woman with a history of Hashimoto's thyroiditis, who, following the onset of nephrotic syndrome revealing her lupus disease, subsequently developed clinical and laboratory features consistent with CVID, alongside recurrent lupus flares. Her initial therapeutic management was intricate, ultimately resulting in stable remission achieved through monthly immunoglobulin infusions.</div></div><div><h3>Conclusion</h3><div>This case illustrates the diagnostic and therapeutic difficulty of lupus disease and a common variable immune deficiency.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 168-172"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}